Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Public ClinicalTrials.gov record NCT04202679. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
Study identification
- NCT ID
- NCT04202679
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Interventions
- Dupilumab SAR231893 Drug
- Placebo Drug
- Moisturizers Drug
- Low to medium potent topical corticosteroids Drug
- Topical calcineurin inhibitors Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 15, 2020
- Primary completion
- Aug 29, 2021
- Completion
- Nov 21, 2021
- Last update posted
- Sep 16, 2025
2020 – 2021
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number :8400054 | Fort Smith | Arkansas | 72916 | — |
| Investigational Site Number :8400008 | Sacramento | California | 95816 | — |
| Investigational Site Number :8400005 | Pembroke Pines | Florida | 33028 | — |
| Investigational Site Number :8400002 | Plainfield | Indiana | 46168 | — |
| Investigational Site Number :8400003 | Baltimore | Maryland | 21205 | — |
| Investigational Site Number :8400006 | East Windsor | New Jersey | 08520 | — |
| Investigational Site Number :8400001 | Sugar Land | Texas | 77479 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04202679, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04202679 live on ClinicalTrials.gov.